An expert panel of 3 independent endocrinologists reviewed all reported thyroid-related laboratory abnormalities and AEs from the CARE-MS trials.
Over 6 years, 378 of 811 (47%) patients treated with alemtuzumab had a laboratory abnormality (n=36) or thyroid AE (n=342; 44 serious). A consensus on thyroid AEs was reached in 292 cases, adjudicated as follows:
- Graves’ disease: 40%;
- Hashimoto’s disease: 17%;
- transient thyroiditis: 8%;
- Graves’ disease switching to hypothyroidism 6%;
- Hashimoto’s disease switching to hyperthyroidism: 3%; and
- uncertain: 2%.
More than 97% of thyroid AEs were detected within 4 years of the last alemtuzumab course; 83% within 2 years. Patients with or without thyroid AEs received similar numbers of alemtuzumab courses. MS disease outcomes were similar in both groups in terms of annualised relapse rate, EDSS score change, brain volume loss, and being disease activity-free on MRI.
Treatment of thyroid AEs consisted of oral thyroid medications in 84%, primarily levothyroxine/levothyroxine sodium (64%) or thiamazole (43%). Another 11% underwent thyroidectomy, 9% had radioiodine therapy. At the most recent follow-up, cases were recovered (53%), ongoing (46%), or unknown (0.3%).
- Dayan C, et al. Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data. MSVirtual 2020, Abstract P0128.
Posted on
Previous Article
« Safety and efficacy of dimethyl fumarate: 13 years of follow-up Next Article
Management of progressive MS with approved DMT »
« Safety and efficacy of dimethyl fumarate: 13 years of follow-up Next Article
Management of progressive MS with approved DMT »
Table of Contents: MS Virtual 2020
Featured articles
Registry participation can enhance quality of rheumatology care
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
T2T approach in women with RA associated with increased fertility
Positive results for vagus nerve stimulation in RA
Machine learning to aid evaluation of ANA pattern and titer
ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease
Registry participation can enhance quality of rheumatology care
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
November 8, 2019
Siponimod delays time to wheelchair
December 20, 2022
Study fails to show non-inferiority of rituximab to ocrelizumab
December 9, 2021
Charcot Award 2021: Progressive MS, a personal perspective
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com